email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
781 - 795
of 3615 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
OcuMension Approved to Launch Novel Uveitis Therapy in China
$5.00
Available
Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines
$5.00
Available
MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots
$5.00
Available
CANbridge Says Anti-C5 mAb Shuts Down Complement Activity
$5.00
Available
Joincare Plans IPO on the SIX Swiss Stock Exchange
$5.00
Available
Clover Starts Phase III Trial of COVID Vaccine as a Booster to Other Vaccines
$5.00
Available
I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio
$5.00
Available
WinHealth Acquires Two Rare Disease Therapies from Quoin Pharma
$5.00
Available
Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy
$5.00
Available
Alphamab Starts China Trial of PD-L1/OX40 Bispecific for Solid Tumors
$0.00
Available
Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars
$5.00
Available
META Raises $15 Million to Develop Small Molecule Immunometabolism Drugs
$5.00
Available
Everest Approved to Launch ADC for Triple-Negative Breast Cancer in China
$5.00
Available
Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers
$5.00
Available
Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers
$5.00
Available